Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glucagon-like peptide-1 inhalation - MannKind Corporation

Next Previous
Search
Drug Profile

Glucagon-like peptide-1 inhalation - MannKind Corporation

Alternative Names: GLP-1/Technosphere®; MKC 253; MKC253 Inhalation Powder

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MannKind Corporation
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 28 Feb 2011 Discontinued - Phase-I for Type-2 diabetes mellitus in Netherlands (Inhalation)
  • 02 Oct 2009 Efficacy data from a phase I trial in Type-2 diabetes mellitus, comparing the effects of MKC 253 with exenatide presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD-2009)
  • 09 Jun 2009 Pharmacodynamics and pharmacokinetics data from phase I trials in Healthy volunteers and Type-2 diabetes mellitus presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009) ,,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top